Interventions for angle-closure glaucoma: An evidence-based update

Seang Mei Saw, Gus Gazzard, David S Friedman

Research output: Contribution to journalArticle

Abstract

Purpose: To assess the interventions to treat acute angle closure (AAC) and primary angle closure (PAC) with or without glaucomatous optic neuropathy. Clinical Relevance: Primary angle closure is one of the leading causes of blindness in East Asia. At present, there are few clinical guidelines on the optimal treatment of AAC or PAC in the affected or contralateral eye. Methods: All randomized clinical trials, prospective controlled clinical trials, nonprospective controlled clinical trials, and retrospective case series with >50 cases that evaluated treatments for AAC or PAC were included. Studies published in the English language were identified from MEDLINE, PubMed, EMBASE, and the Cochrane Collaborations, as well as by a hand search of the reference lists of important articles. Results: Nine randomized clinical trials and 24 nonrandomized clinical trials and large case series were evaluated. Laser peripheral iridotomy (LPI) has been found to be as effective as surgical peripheral iridectomy in randomized clinical trials of the affected and contralateral eyes of AAC or PAC patients with or without evidence of glaucoma. In another randomized clinical trial, latanoprost was found to decrease intraocular pressure (IOP) more than timolol for PAC in patients for whom LPI alone failed. Conclusions: This review suggests that LPI should be recommended for the treatment of affected and contralateral eyes of AAC patients. In patients with PAC and insufficient treatment with LPI, latanoprost eye drops may decrease IOP more than timolol. There is still insufficient evidence about other interventions for the treatment of AAC and PAC.

Original languageEnglish (US)
Pages (from-to)1869-1879
Number of pages11
JournalOphthalmology
Volume110
Issue number10
DOIs
StatePublished - Oct 1 2003

Fingerprint

Angle Closure Glaucoma
latanoprost
Lasers
Randomized Controlled Trials
Timolol
Controlled Clinical Trials
Intraocular Pressure
Iridectomy
Therapeutics
Optic Nerve Diseases
Far East
Ophthalmic Solutions
Blindness
PubMed
MEDLINE
Glaucoma
Language
Guidelines

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Interventions for angle-closure glaucoma : An evidence-based update. / Saw, Seang Mei; Gazzard, Gus; Friedman, David S.

In: Ophthalmology, Vol. 110, No. 10, 01.10.2003, p. 1869-1879.

Research output: Contribution to journalArticle

Saw, Seang Mei ; Gazzard, Gus ; Friedman, David S. / Interventions for angle-closure glaucoma : An evidence-based update. In: Ophthalmology. 2003 ; Vol. 110, No. 10. pp. 1869-1879.
@article{feba44e69ebb4913a0c849014480b1fb,
title = "Interventions for angle-closure glaucoma: An evidence-based update",
abstract = "Purpose: To assess the interventions to treat acute angle closure (AAC) and primary angle closure (PAC) with or without glaucomatous optic neuropathy. Clinical Relevance: Primary angle closure is one of the leading causes of blindness in East Asia. At present, there are few clinical guidelines on the optimal treatment of AAC or PAC in the affected or contralateral eye. Methods: All randomized clinical trials, prospective controlled clinical trials, nonprospective controlled clinical trials, and retrospective case series with >50 cases that evaluated treatments for AAC or PAC were included. Studies published in the English language were identified from MEDLINE, PubMed, EMBASE, and the Cochrane Collaborations, as well as by a hand search of the reference lists of important articles. Results: Nine randomized clinical trials and 24 nonrandomized clinical trials and large case series were evaluated. Laser peripheral iridotomy (LPI) has been found to be as effective as surgical peripheral iridectomy in randomized clinical trials of the affected and contralateral eyes of AAC or PAC patients with or without evidence of glaucoma. In another randomized clinical trial, latanoprost was found to decrease intraocular pressure (IOP) more than timolol for PAC in patients for whom LPI alone failed. Conclusions: This review suggests that LPI should be recommended for the treatment of affected and contralateral eyes of AAC patients. In patients with PAC and insufficient treatment with LPI, latanoprost eye drops may decrease IOP more than timolol. There is still insufficient evidence about other interventions for the treatment of AAC and PAC.",
author = "Saw, {Seang Mei} and Gus Gazzard and Friedman, {David S}",
year = "2003",
month = "10",
day = "1",
doi = "10.1016/S0161-6420(03)00540-2",
language = "English (US)",
volume = "110",
pages = "1869--1879",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - Interventions for angle-closure glaucoma

T2 - An evidence-based update

AU - Saw, Seang Mei

AU - Gazzard, Gus

AU - Friedman, David S

PY - 2003/10/1

Y1 - 2003/10/1

N2 - Purpose: To assess the interventions to treat acute angle closure (AAC) and primary angle closure (PAC) with or without glaucomatous optic neuropathy. Clinical Relevance: Primary angle closure is one of the leading causes of blindness in East Asia. At present, there are few clinical guidelines on the optimal treatment of AAC or PAC in the affected or contralateral eye. Methods: All randomized clinical trials, prospective controlled clinical trials, nonprospective controlled clinical trials, and retrospective case series with >50 cases that evaluated treatments for AAC or PAC were included. Studies published in the English language were identified from MEDLINE, PubMed, EMBASE, and the Cochrane Collaborations, as well as by a hand search of the reference lists of important articles. Results: Nine randomized clinical trials and 24 nonrandomized clinical trials and large case series were evaluated. Laser peripheral iridotomy (LPI) has been found to be as effective as surgical peripheral iridectomy in randomized clinical trials of the affected and contralateral eyes of AAC or PAC patients with or without evidence of glaucoma. In another randomized clinical trial, latanoprost was found to decrease intraocular pressure (IOP) more than timolol for PAC in patients for whom LPI alone failed. Conclusions: This review suggests that LPI should be recommended for the treatment of affected and contralateral eyes of AAC patients. In patients with PAC and insufficient treatment with LPI, latanoprost eye drops may decrease IOP more than timolol. There is still insufficient evidence about other interventions for the treatment of AAC and PAC.

AB - Purpose: To assess the interventions to treat acute angle closure (AAC) and primary angle closure (PAC) with or without glaucomatous optic neuropathy. Clinical Relevance: Primary angle closure is one of the leading causes of blindness in East Asia. At present, there are few clinical guidelines on the optimal treatment of AAC or PAC in the affected or contralateral eye. Methods: All randomized clinical trials, prospective controlled clinical trials, nonprospective controlled clinical trials, and retrospective case series with >50 cases that evaluated treatments for AAC or PAC were included. Studies published in the English language were identified from MEDLINE, PubMed, EMBASE, and the Cochrane Collaborations, as well as by a hand search of the reference lists of important articles. Results: Nine randomized clinical trials and 24 nonrandomized clinical trials and large case series were evaluated. Laser peripheral iridotomy (LPI) has been found to be as effective as surgical peripheral iridectomy in randomized clinical trials of the affected and contralateral eyes of AAC or PAC patients with or without evidence of glaucoma. In another randomized clinical trial, latanoprost was found to decrease intraocular pressure (IOP) more than timolol for PAC in patients for whom LPI alone failed. Conclusions: This review suggests that LPI should be recommended for the treatment of affected and contralateral eyes of AAC patients. In patients with PAC and insufficient treatment with LPI, latanoprost eye drops may decrease IOP more than timolol. There is still insufficient evidence about other interventions for the treatment of AAC and PAC.

UR - http://www.scopus.com/inward/record.url?scp=0141513665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141513665&partnerID=8YFLogxK

U2 - 10.1016/S0161-6420(03)00540-2

DO - 10.1016/S0161-6420(03)00540-2

M3 - Article

C2 - 14522756

AN - SCOPUS:0141513665

VL - 110

SP - 1869

EP - 1879

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 10

ER -